3 Min Read

Medicine choice for people with obesity welcomed with appropriate safeguards

Lead image for Medicine choice for people with obesity welcomed with appropriate safeguards

GLP-1 medicines have been extremely popular across the globe for people managing diabetes or struggling with obesity. The Therapeutic Goods Administration's approval of the Wegovy tablet for use in Australia is welcomed, and supply must come with protections for patients who need face to face care from health professionals.

Wegovy pill cleared for Australia

Australian patients will soon have another treatment option for obesity, with the Therapeutic Goods Administration registering an oral tablet formulation of Wegovy.

The decision marks the first time a GLP-1 medicine has been approved in Australia in tablet form specifically for weight management, providing a non-injectable alternative to weekly injections.

Made by Novo Nordisk, oral Wegovy contains semaglutide, the same active ingredient as injectable Wegovy. Four tablet strengths have been approved: 1.5 mg, 4 mg, 9 mg and 25 mg.

The tablet is approved for adults for chronic weight management and cardiovascular risk reduction in eligible patients. Unlike injectable Wegovy, the tablet is not currently approved for children and adolescents under 18.


Guild welcomes choice, calls for safeguards

Pharmacy Guild of Australia National President Professor Trent Twomey welcomed the additional treatment option but said its arrival also highlighted the need for strong safeguards around how high-demand GLP-1 medicines are prescribed and dispensed.

“This is a blockbuster medicine, and international experience tells us it’s going to be enormously popular with patients with obesity.

“Like all GLP-1s, this is powerful medicine that should be prescribed by a GP and dispensed by a community pharmacy, face to face.”

Professor Twomey said the growth of direct-to-consumer and vertically integrated models created a risk that commercial incentives could become entangled with clinical decisions.

“At the moment there’s a regulatory gap that means other models of care can emerge that prioritise the profits of multinational drug companies. We’ve seen the problems created by irresponsible prescribing of medicinal cannabis and peptides.

“It’s time for the government to act. It needs to make sure that patients prescribed these medicines receive a proper clinical assessment, face-to-face care and ongoing monitoring from their GP and pharmacist.

“Medicines aren't ordinary consumer products and pharmacies aren't fulfilment centres. Access must never be reduced to a click-and-ship transaction.”

The Guild recently raised concerns about LillyDirect and is calling for stronger protections around direct-to-consumer supply models.

It wants safeguards that:

  • require appropriate clinical assessment, including face-to-face consultation where clinically warranted, before medicines are prescribed
  • strengthen regulation of online and direct-to-consumer supply models, including manufacturer-operated models
  • protect patients’ choice of pharmacy and meaningful access to a pharmacist
  • ensure patients receive appropriate follow-up and ongoing monitoring.

Not simply Wegovy without the needle

For community pharmacists, the new formulation will also create important counselling considerations.

The tablet is taken once daily rather than once weekly. Treatment starts at 1.5 mg daily before stepping through 4 mg and 9 mg to a 25 mg maintenance dose, with at least a month at each dose level.


Administration is important.

The tablet must be taken after fasting for at least eight hours and swallowed with no more than 120 mL of water. Patients must then wait at least 30 minutes before eating, drinking or taking other oral medicines.

That means the non-injectable formulation will not necessarily be simpler for every patient. Pharmacists will have an important role in explaining the administration requirements and helping patients understand how the medicine fits alongside their other treatments.


Not the first oral semaglutide

Oral semaglutide itself is not new in Australia. Rybelsus is already registered for type 2 diabetes. The new Wegovy tablets, however, have different strengths and indications and are not interchangeable with Rybelsus.

The tablets will also sit alongside injectable Wegovy, which has been registered in Australia for weight management for several years.


When will pharmacies see it?

Registration does not mean stock will arrive in pharmacies immediately.

The TGA still needs to review packaging and production processes before the medicine can be released. Novo Nordisk has indicated it expects the tablet to become available in Australia before the end of 2026, although the timing has not yet been confirmed.

Australian pricing has also not yet been announced.

Given the intense interest in GLP-1 medicines, community pharmacists can expect questions about the tablet, how it differs from injectable Wegovy and whether patients can move between formulations.

For the Guild, the arrival of another GLP-1 option also reinforces a broader principle: innovation should give patients more treatment options, but greater convenience should never come at the expense of appropriate clinical assessment, pharmacist counselling, continuity of care or patient choice.


Australasian Pharmacy

Like what you see?

Check out the Australasian Pharmacy magazine for more great articles.